Skip to main content
logo
Kailera Therapeutics, Inc. (KLRA)
NASDAQ: KLRA · Real-Time Price · USD
11.43
+0.18 (1.60%)
Oct 19, 2026, 4:00 PM EDT - Market closed

Kailera Therapeutics Balance Sheet

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Cash & Equivalents
130.3160.27175.18
Short-Term Investments
786.44385.79-
Cash & Short-Term Investments
916.74546.06175.18
Cash Growth
-211.72%-
Other Receivables
6.112.73-
Receivables
6.112.73-
Prepaid Expenses
5.927.522.09
Other Current Assets
0.41.230.34
Total Current Assets
929.17557.54177.61
Property, Plant & Equipment
11.6512.420.68
Long-Term Investments
255.08106.67-
Long-Term Deferred Charges
-2.60.15
Other Long-Term Assets
15.5213.07-
Total Assets
1,211692.29178.45

Liabilities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Accounts Payable
19.27.532.01
Accrued Expenses
62.6836.922.23
Current Portion of Leases
1.051.040.51
Other Current Liabilities
0.720.922.16
Total Current Liabilities
83.6546.416.91
Long-Term Leases
9.179.71-
Other Long-Term Liabilities
0.140.27-
Total Liabilities
92.9556.396.91

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Additional Paid-In Capital
1,67911.980.94
Retained Earnings
-558.84-368.67-219.71
Comprehensive Income & Other
-1.790.23-
Total Common Equity
1,118-356.46-218.77
Shareholders' Equity
1,118635.91171.53
Total Liabilities & Equity
1,211692.29178.45

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Total Debt
10.2210.750.51
Net Cash (Debt)
1,162641.98174.67
Net Cash Growth
-267.54%-
Net Cash Per Share
8.9633703.01-
Filing Date Shares Outstanding
129.640.02-
Total Common Shares Outstanding
129.620.02-
Working Capital
845.52511.13170.7
Book Value Per Share
8.63-18713.67-
Tangible Book Value
1,118-356.46-218.77
Tangible Book Value Per Share
8.63-18713.67-
Machinery
-1.490.26
Leasehold Improvements
-0.56-
SEC Filings: 10-K · 10-Q